It has been shown that different mutational statuses and expression patterns of wild type may lead to different clinical outcomes of the immune response, with wild-type TP53 patients having a higher sensitivity to radiotherapy for HNSCC (Cao et al., 2019). Here, TP53 is linked to head and neck squamous cell carcinoma.